查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425122

全球体学实验室服务市场：预测（2024-2029）

Omics Lab Services Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2022 年，体学实验室服务市场价值将达到 988.42 亿美元，预测期内复合年增长率为 15.17%。

以-omics结尾的生物科学研究，如基因组学、转录组学、蛋白质组学、代谢组学等，称为体学。基因组研究探索基因组的结构、功能、演化和作图，重点是在酵素和信使分子的帮助下控制蛋白质生产的基因的表征和定量。除了化学特性之外，体学还包括每个 RNA 分子的数量和浓度。

体学技术在癌症研究的优势

基因组、转录、蛋白质组和代谢水平的复杂相互作用参与癌症发病机制。由于综合多组体学分析，我们对肿瘤复杂生物学的理解，包括免疫逃脱、肿瘤发展、肿瘤异质性、肿瘤微环境和抗治疗性，已大大增加。体学技术有可能对癌症研究极为有益，因为它们提供了前所未有的机会在多个病理和分子层面上说明癌症生物学。汇集多个组体学的资料是了解致癌机制的重要第一步。高通量技术的进步使得多种体学方法，包括基因组学、表观基因、转录组学、蛋白质组学和代谢组学，可用于分析不同但互补的生物层。

基因组学和巨量资料分析的创新

随着医疗保健巨量资料领域的快速扩张，基于案例的研究正在被广泛的资料驱动研究所取代。由于巨量资料依赖新资料标准、技术和相关研究的发展，因此巨量资料应用的未来发展在当前的医疗革命中具有可预测的潜力。极其庞大且快速扩展的生物体学资料（基因组学、蛋白质组学、转录组学、代谢组学、醣质学等）和临床资料的处理和解释提供了重大障碍和可能性，而这些数据为解决问题带来了新的运算网关。

磊晶的日益普及

在预测期内，磊晶类别预计将以最快的速度发展。提供体学实验室服务的公司正致力于使其产品和服务多样化，以吸引体学实验室服务市场。例如，2022 年 1 月，Eisbach Bio GmbH 和德克萨斯大学MD 安德森癌症中心宣布了一项策略，共同识别和创建精准肿瘤疗法，针对肿瘤基因组进化所必需的合成命运引擎。我们已经开始了研究合作伙伴关係。透过此次合作，艾斯巴赫和 MD 安德森癌症中心的治疗发现部门将结合最先进的发现平台和变构测定技术，特异性抑制具有特定基因改变的癌症的基因组复製和 DNA 修復。那将

转录组学的普及

与基因组学领域相比，转录组学在单细胞转录组学分析中的高利用率说明了体学实验室服务市场的扩张。雷射捕获晶粒（LCM）等自动化定序方法可以满足生物材料核酸定序的需求，并正在推动空间基因组学产业的发展。保存遗传或地理资料以供以后使用的尖端定序技术的发展也受到对组织异质性更深入了解的启发。预计这一因素将在整个预期期间刺激体学实验室服务市场的扩张。

政府对基因组学计划的投资

据澳洲政府称，医学遗传学研究已从基因组学健康未来使命获得 5.01 亿美元。基因组学有可能彻底改变临床医学。基因组学健康未来使命以已完成的研究为基础，旨在展示遗传学和相关技术如何支持患者和卫生系统。随着基因组学的使用变得更加广泛，客製化和改善疾病管理的机会将会增加。受人类基因计划的启发，生物技术系 (DBT) 于 2020 年 1 月 3 日启动了雄心勃勃的「印度基因计划」(GIP)。为了创建参考基因组，GIP 正在从全国各地的印度居民收集 10,000 个基因样本。

北美组体学实验室服务市场预计将稳定成长

北美体学实验室服务市场的扩张预计将受到临床研究中基因检测日益增长的需求的推动，包括针对糖尿病和癌症等疾病的个人化医疗。例如，根据美国疾病管制与预防中心的数据，美国癌症协会利用中央癌症登记处的发病率资料和国家健康统计中心的死亡率资料估计了美国新发癌症病例和死亡人数每年估计并彙编有关基于人群的癌症发生率和结果的最新资讯。到 2023 年，美国可能将有 609,820 例癌症相关死亡病例和 1,958,310 例新癌症病例。

本公司提供的体学实验室服务

  • 安捷伦：灵活的蛋白质体学分析工具，可最大限度地提高通量和灵敏度。全面的代谢组学分析解决方案可促进您的运作。创新的脂质组学分析工具使复杂的程序变得更加简单。
  • Cerba Research：Cerba Research 为临床前、转化和临床研究计划提供组织组体学服务。这些高度适应性的系统提供了对完整组织、整体或空间、感兴趣区域和组织切片上特定细胞群中的蛋白质和转录本的定量研究。 nCounter(R) 和 GeoMx(R) 奈米串平台将安装在实验室中，为每个请求提供最合适的资料集。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章体学实验室服务市场：依服务分类

  • 介绍
  • 基因组学
  • 蛋白质体学
  • 转录组
  • 代谢组学
  • 磊晶

第六章体学实验室服务市场：依产品

  • 介绍
  • 单发
  • 重复
  • 延续

第七章体学实验室服务市场：依最终用途

  • 介绍
  • 硬体设备
  • 测试/实验室
  • 分析

第八章体学实验室服务市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 併购/协议/合作
  • 供应商竞争力矩阵

第十章 公司简介

  • Northumbria University
  • Mary Ann Liebert
  • Agilent
  • Omics Lab
  • Neogen Corporation
  • DrOmics Labs
  • NeoGenomics Laboratories
  • Vizgen
  • Dhiti Omics
  • Perkin Elmer
简介目录
Product Code: KSI061616222

The omics lab services market was valued at US$98.842 billion in 2022 and is expected to grow at a CAGR of 15.17% during the forecast period.

A biological science branch of study that ends in -omics, such as genomics, transcriptomics, proteomics, or metabolomics, is referred to as an omics. Genomic research focuses on characterizing and quantifying genes, which regulate the creation of proteins with the aid of enzymes and messenger molecules, and explores the structure, function, evolution, and mapping of genomes. In addition to the chemical identities, it also contains the quantity or concentration of each RNA molecule.

Benefits of omics technologies in cancer research

Complex interactions at the genomic, transcriptional, proteomic, and metabolic levels play a role in the etiology of cancer. The comprehension of the intricate biology of tumors, including immune evasion, tumor development, tumor heterogeneity, the tumor microenvironment, and treatment resistance, has considerably increased as a result of integrative multi-omics analysis. Since they provide an unprecedented chance to describe cancer biology at several pathological and molecular levels, omics technologies have the potential to be extremely beneficial to cancer research. Pooling data from several omics is an essential first step to understanding the mechanisms behind oncogenesis. With high-throughput technology advancements, a variety of omics methods, including genomes, epigenomics, transcriptomics, proteomics, and metabolomics, are accessible to analyze diverse yet complementary biological layers.

Innovations in Genomics and Big Data Analytics

Case-based studies are being replaced with extensive, data-driven research due to the rapidly expanding field of big data in health care. Big data applications' future development has predictable potential in the present healthcare revolution since big data is dependent on the development of new data standards, technology, and related research. The processing and interpretation of very vast, quickly expanding sets of biological omics data (genomics, proteomics, transcriptomics, metabolomics, glycomics, etc.) and clinical data provide significant obstacles as well as possibilities, and they also bring up new computational gateways to solve these problems.

Growing popularity in epigenetics

Throughout the projection period, the epigenetics category is anticipated to develop at the quickest rate. Businesses providing omics lab services are focusing on diversifying their product and service offerings to appeal to this omics lab services market. For instance, in January 2022, Eisbach Bio GmbH and the University of Texas MD Anderson Cancer Centre launched a strategic research partnership to collaboratively identify and create precision oncology therapies that target synthetic fatal engines crucial to tumor genome evolution. Through this partnership, Eisbach and MD Anderson's Therapeutics Discovery division will combine their cutting-edge discovery platforms and allosteric assay technologies to develop drugs that specifically disrupt genome replication and DNA repair in cancers carrying specific genetic alterations.

Rising adoption of transcriptomics

The higher usage of transcriptomics for single-cell transcriptomics analysis compared to the genomics sector accounts for the omics lab services market expansion. Automated sequencing methods like the laser capture microdissection technique (LCM) have been able to meet the demand for nucleic acid sequencing of biological materials, which has fueled the growth of the spatial genomics industry. The development of cutting-edge sequencing technologies to save genetic or geographical data for later use has also been inspired by a deeper knowledge of tissue heterogeneity. It is projected that this element would stimulate omics lab services market expansion throughout the anticipated period.

Government investments in genomics projects

According to the Australian Government, research in genetic medicine is receiving $500.1 million from the Genomics Health Futures Mission. The science of genomics has the potential to revolutionize clinical medicine. To show how genetics and associated technologies assist patients and the healthcare system, the Genetics Health Futures Mission will expand on already completed research. Opportunities to customize and improve illness management will grow as genomics usage becomes more pervasive. The Department of Biotechnology (DBT) launched the ambitious "Genome India Project" (GIP) on January 3rd, 2020, drawing inspiration from the Human Genome Project. To create a reference genome, the GIP seeks to gather 10,000 genetic samples from Indian residents throughout the country.

In North America, it is projected that the omics lab services market will grow steadily.

Omics lab services market expansion in North America is anticipated to be fueled by the growing demand for genetic testing in clinical studies including personalized healthcare for diseases like diabetes and cancer. For instance, according to the Centers for Disease Control and Prevention, using incidence data from central cancer registries and mortality data from the National Centre for Health Statistics, the American Cancer Society estimates the number of new cancer cases and deaths in the United States each year and compiles the most recent information on population-based cancer occurrence and outcomes. In 2023, there will likely be 609,820 cancer-related fatalities and 1,958,310 new cases of cancer in the United States.

Omics Lab Services offered by Companies

  • Agilent, Flexible proteomics analysis tools for the maximum throughput and sensitivity. Solutions for comprehensive metabolomics analysis advance operations. Innovative lipidomics analysis tools make complex procedures simpler.
  • Cerba Research, Tissue omics services are provided by Cerba Research for pre-clinical, translational, and clinical research projects.These adaptable systems provide the quantitative study of proteins and transcripts in complete tissue, either in bulk or spatially in regions of interest and particular cell populations on tissue slices. The nCounter® and GeoMx® Nanostring platforms are installed in labs to deliver the most pertinent datasets for each request.

Market Key Developments

  • In September 2023, MGI, a firm dedicated to creating the fundamental tools and technology to drive life science, unveiled the DCS Lab Initiative to support expansive leading multi-omics laboratories and advance vital scholarly endeavors. As part of the program, the business will make products based on DNBSEQ technology available to chosen research organizations worldwide for a variety of applications, including DNA sequencing, cell omics, and spatial omics.
  • In April 2023, a deal was reached between Mission Bio, Inc., a leader in high-throughput single-cell DNA and multi-omics analysis, and Fulgent Genetics, a technology-based company with a reputable clinical diagnostics and therapeutic development business.

Segmentation:

By Services

  • Genomics
  • Proteomics
  • Transcriptomic
  • Metabolomics
  • Epigenetics

By Product

  • One-Off
  • Repeat
  • Continuous

By End-Use

  • Hardware Equipment
  • Testing/Lab
  • Analytics

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. OMICS LAB SERVICES MARKET, BY SERVICES

  • 5.1. Introduction
  • 5.2. Genomics
  • 5.3. Proteomics
  • 5.4. Transcriptomic
  • 5.5. Metabolomics
  • 5.6. Epigenetics

6. OMICS LAB SERVICES MARKET, BY PRODUCT

  • 6.1. Introduction
  • 6.2. One-Off
  • 6.3. Repeat
  • 6.4. Continuous

7. OMICS LAB SERVICES MARKET, BY END-USE

  • 7.1. Introduction
  • 7.2. Hardware Equipment
  • 7.3. Testing/Lab
  • 7.4. Analytics

8. OMICS LAB SERVICES MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Northumbria University
  • 10.2. Mary Ann Liebert
  • 10.3. Agilent
  • 10.4. Omics Lab
  • 10.5. Neogen Corporation
  • 10.6. DrOmics Labs
  • 10.7. NeoGenomics Laboratories
  • 10.8. Vizgen
  • 10.9. Dhiti Omics
  • 10.10. Perkin Elmer